The FDA gives an orphan drug designation to drug candidates that treat a disease that affects less than 200,000 persons in the United States.
The designation is designed to give financial incentives to drugmakers so that drugs for rare diseases will be developed. Those include:
- A 50% tax credit on clinical trial costs
- A break from paying Prescription Drug User Fee Act fees
- The all-important seven years of exclusive sales
Related Fool Articles
Recent Mentions on Fool.com
- 3 Stocks I'll Buy if the Market Crashes
- A Quick Look at Celgene Corporation's Drug Development Pipeline
- Better Dividend Stock: Amgen, Inc. or AbbVie Inc.?
- Up 113% in 2014, Can This Medical Marijuana Stock Keep Growing?
- 3 Best Stocks for Investing in Biotech
- Why Auxilium Pharmaceuticals Inc. Stock Is Skyrocketing Today